Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 276 Lung Neoplasms 106 Adenocarcinoma of Lung 28 Mesothelioma, Malignant 22 Neoplasms 19 Neoplasm Metastasis 18 Breast Neoplasms 13 Brain Neoplasms 13 Mesothelioma 10 Head and Neck Neoplasms 10 Ovarian Neoplasms 8 Colorectal Neoplasms 8 Recurrence 7 Adenocarcinoma, Bronchiolo-Alveolar 7 Small Cell Lung Carcinoma 6 NSCLC 6 Adenocarcinoma 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Meningeal Carcinomatosis 5 Carcinoma 5 Urinary Bladder Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Solitary Fibrous Tumor, Pleural 4 Sarcoma 4 Pancreatic Neoplasms 4 Non-small Cell Lung Cancer Metastatic 4 Laryngeal Diseases 4 Carcinoma, Transitional Cell 4 Uterine Neoplasms 3 Uterine Cervical Neoplasms 3

Interventions

Nivolumab 3 palbociclib 2 Ipilimumab 2 Imatinib Mesylate 2 relatlimab 1 pembrolizumab 1 camrelizumab 1 apatinib 1 Specimen Handling 1 Radiotherapy 1 Radiation 1 Protons 1 Proton Therapy 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Immunoglobulin G 1 Disulfides 1 Dasatinib 1 Cetuximab 1 CTLA-4 Antigen 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Chordoma × Pemetrexed × Clear all

NCT06794645 2025-01-27

Pembrolizumab and Pemetrexed for Progressive Chordoma

Saint John's Cancer Institute

Phase 2 Recruiting

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡